# Scientific Summary

**Prompt:** Advances in CRISPR-Cas gene editing and implications for rare genetic diseases

**Summary:**
Advances in CRISPR-Cas gene editing have significantly impacted the field of rare genetic diseases, offering new avenues for treatment and research. The paper "Current progress in CRISPR-Cas systems for rare diseases" highlights the transformative potential of CRISPR-Cas technology in molecular biology and genetics, enabling precise gene editing for research, animal models, and patient therapies. This technology allows for the modification of genetic codes, which is crucial for understanding and potentially curing rare genetic disorders.

The study "Novel CRISPR-Cas9 iPSC knockouts for PCCA and PCCB genes: advancing propionic acidemia research" demonstrates the application of CRISPR-Cas9 in creating induced pluripotent stem cell (iPSC) models for propionic acidemia, a rare metabolic disorder. These models are essential for studying the disease and developing therapeutic strategies.

In "Reporter Mice for Gene Editing: A Key Tool for Advancing Gene Therapy of Rare Diseases," the development of reporter mice is discussed. These mice are engineered to express reporter genes that indicate the efficiency of gene editing, providing a valuable tool for optimizing CRISPR-based therapies for rare diseases.

The article "Challenges and progress related to gene editing in rare skin diseases" explores the use of CRISPR technology in treating genodermatoses, a group of inherited skin disorders. This research underscores the potential of CRISPR to offer long-term solutions for conditions that currently have only transient treatments.

Finally, "Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy" emphasizes the global impact of CRISPR-Cas9 technology, particularly in countries like India, where rare genetic disorders affect millions. The paper highlights the promise of CRISPR-based treatments in providing hope for effective therapies for these life-threatening conditions.

Collectively, these studies illustrate the profound implications of CRISPR-Cas advancements in addressing rare genetic diseases, offering new insights and therapeutic possibilities that were previously unattainable.

---

## Information on the total number of items extracted, including those identified as most relevant by the agent (10)

### 1. Genomic medicine and personalized treatment: a narrative review.
- **Date:** 2025-02-13
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/40213198](https://pubmed.ncbi.nlm.nih.gov/40213198)
- **DOI:** 10.1097/MS9.0000000000002965
- **Abstract:** Genomic medicine, which integrates genomics and bioinformatics into clinical care and diagnostics, is transforming healthcare by enabling personalized treatment approaches. Advances in technologies such as DNA sequencing, proteomics, and computational power have laid the foundation for individualized therapies that account for genetic variations influencing disease risk, progression, and treatment response. This review explores the historical milestones leading to current applications of genomic...

### 2. Novel CRISPR-Cas9 iPSC knockouts for PCCA and PCCB genes: advancing propionic acidemia research.
- **Date:** 2025-03-05
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/40044943](https://pubmed.ncbi.nlm.nih.gov/40044943)
- **DOI:** 10.1007/s13577-025-01193-z
- **Abstract:** Propionic acidemia (PA) is a rare autosomal recessive metabolic disorder caused by mutations in the PCCA and PCCB genes, which encode subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC). This enzyme deficiency leads to the accumulation of toxic metabolites, resulting in severe metabolic dysfunction. To create ideal in vitro disease models of PA with isogenic controls and provide a robust platform for therapeutic research, we generated two induced pluripotent stem cell (iPSC) lin...

### 3. Current progress in CRISPR-Cas systems for rare diseases.
- **Date:** 2024-08-31
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/39824580](https://pubmed.ncbi.nlm.nih.gov/39824580)
- **DOI:** 10.1016/bs.pmbts.2024.07.019
- **Abstract:** The groundbreaking CRISPR-Cas gene editing method permits exact genetic code alteration. The "CRISPR" DNA protects bacteria from viruses. CRISPR-Cas utilizes a guide RNA to steer the Cas enzyme to the genome's gene editing target. After attaching to a sequence, Cas enzymes cleave DNA to insert, delete, or modify genes. The influence of CRISPR-Cas technology on molecular biology and genetics is profound. It allows for gene function research, animal disease models, and patient genetic therapy. Gen...

### 4. Reporter Mice for Gene Editing: A Key Tool for Advancing Gene Therapy of Rare Diseases.
- **Date:** 2024-09-09
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/39273078](https://pubmed.ncbi.nlm.nih.gov/39273078)
- **DOI:** 10.3390/cells13171508
- **Abstract:** Most rare diseases are caused by mutations and can have devastating consequences. Precise gene editing by CRISPR/Cas is an exciting possibility for helping these patients, if no irreversible developmental defects have occurred. To optimize gene editing therapy, reporter mice for gene editing have been generated which, by expression of reporter genes, indicate the efficiency of precise and imprecise gene editing. These mice are important tools for testing and comparing novel gene editing methodol...

### 5. Gene editing in liver diseases.
- **Date:** 2024-07-30
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/39079936](https://pubmed.ncbi.nlm.nih.gov/39079936)
- **DOI:** 10.1002/1873-3468.14989
- **Abstract:** The deliberate and precise modification of the host genome using engineered nucleases represents a groundbreaking advancement in modern medicine. Several clinical trials employing these approaches to address metabolic liver disorders have been initiated, with recent remarkable outcomes observed in patients with transthyretin amyloidosis, highlighting the potential of these therapies. Recent technological improvements, particularly CRISPR Cas9-based technology, have revolutionized gene editing, e...

### 6. Towards a Cure for Diamond-Blackfan Anemia: Views on Gene Therapy.
- **Date:** 2024-05-27
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/38891052](https://pubmed.ncbi.nlm.nih.gov/38891052)
- **DOI:** 10.3390/cells13110920
- **Abstract:** Diamond-Blackfan anemia (DBA) is a rare genetic disorder affecting the bone marrow's ability to produce red blood cells, leading to severe anemia and various physical abnormalities. Approximately 75% of DBA cases involve heterozygous mutations in ribosomal protein (RP) genes, classifying it as a ribosomopathy, with RPS19 being the most frequently mutated gene. Non-RP mutations, such as in GATA1, have also been identified. Current treatments include glucocorticosteroids, blood transfusions, and h...

### 7. Challenges and progress related to gene editing in rare skin diseases.
- **Date:** 2024-03-23
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/38527624](https://pubmed.ncbi.nlm.nih.gov/38527624)
- **DOI:** 10.1016/j.addr.2024.115294
- **Abstract:** Genodermatoses represent a large group of inherited skin disorders encompassing clinically-heterogeneous conditions that manifest in the skin and other organs. Depending on disease variant, associated clinical manifestations and secondary complications can severely impact patients' quality of life and currently available treatments are transient and not curative. Multiple emerging approaches using CRISPR-based technologies offer promising prospects for therapy. Here, we explore current advances ...

### 8. Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy.
- **Date:** 2024-02-01
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/38383973](https://pubmed.ncbi.nlm.nih.gov/38383973)
- **Abstract:** Rare genetic diseases are a group of life-threatening disorders affecting significant populations worldwide and posing substantial challenges to healthcare systems globally. India, with its vast population, is also no exception. The country harbors millions of individuals affected by these fatal disorders, which often result from mutations in a single gene. The emergence of CRISPR-Cas9 technology, however, has ushered in a new era of hope in genetic therapies. CRISPR-based treatments hold the po...

### 9. Next-generation therapeutics for rare genetic disorders.
- **Date:** 2024-04-01
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/38332115](https://pubmed.ncbi.nlm.nih.gov/38332115)
- **DOI:** 10.1093/mutage/geae002
- **Abstract:** The therapeutic potential of the human genome has been explored through the development of next-generation therapeutics, which have had a high impact on treating genetic disorders. Classical treatments have traditionally focused on common diseases that require repeated treatments. However, with the recent advancements in the development of nucleic acids, utilizing DNA and RNA to modify or correct gene expression in genetic disorders, there has been a paradigm shift in the treatment of rare disea...

### 10. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi.
- **Date:** 2023-10-29
- **Source:** PubMed
- **URL:** [https://pubmed.ncbi.nlm.nih.gov/38034032](https://pubmed.ncbi.nlm.nih.gov/38034032)
- **DOI:** 10.1016/j.omtn.2023.102066
- **Abstract:** The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across countries. Recently, COST Action funded the "Genome Editing to treat Human Diseases" (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech firms, and patient advocacy gr...
